How Pharm.D. was paid
$20.2M in total for FY2026, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Options | Other | Total |
|---|---|---|---|---|---|---|
| Eric Venker, M.D., Pharm.D.Chief Executive Officer | $636,618 | $503,345 | — | $19,010,639 | $8,165 | $20,158,767 |
| Tiago GirãoChief Financial Officer | $455,493 | $224,396 | $3,631,717 | $3,293,508 | $11,323 | $7,616,437 |
| Melanie GloriaChief Operating Officer | $495,000 | $245,025 | $1,157,951 | $1,150,095 | $19,041 | $3,067,112 |
| Jay StoutChief Technology Officer | $495,000 | $245,025 | $1,157,951 | $1,150,095 | $17,650 | $3,065,721 |
| Christopher Van TuylChief Legal Officer and Corporate Secretary | $495,000 | $245,025 | $771,962 | $766,726 | $17,064 | $2,295,777 |
| Peter Salzmann, M.D.Former Chief Executive Officer | $39,614 | — | $8,287,949 | $6,269,395 | $737,642 | $15,334,600 |
| Eva Renee BarnettFormer Chief Financial Officer | $26,250 | — | $1,350,946 | $1,462,825 | $387,431 | $3,227,452 |
| Michael Geffner, M.D.Former Chief Medical Officer | $345,521 | — | $2,564,119 | $2,145,870 | $198,579 | $5,254,089 |
What changed and why
- $19M$19,010,639 in option awards was Eric Venker’s largest FY2026 compensation component.
- $303K67:1 was the FY2026 CEO pay ratio, based on median employee compensation of $303,366.
- FY2026 bonuses reflected company performance objectives, with Compensation Committee discretion over payouts.
- FY2026 introduced PSUs for certain executives, tied to two development milestones through March 31, 2029.
- Eric Venker received 1,475,000 CVARs with clinical, service and stock-price vesting conditions.
- 99%Over 99% supported 2025 say-on-pay, and no program changes followed.
Other Immunovant proxy statements
- 2025 proxy statement
Peter Salzmann, M.D. paid $10.7M (+25% on the year), pay ratio 29:1.
Filed Jul 09, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.